Skip to main content

4 Result(s)

within Kana Akiyama Remove this filter

and

  1. No Access

    Article

    Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

    This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2–4 in cisplatin-based chemotherapy.

    Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura… in British Journal of Cancer (2024)

  2. No Access

    Article

    Effect of 0.1% Fluorometholone on the Prevention of Eye Disorders Caused by High-Dose Cytarabine Therapy: a Propensity Score Analysis

    High-dose cytarabine (HiDAC) is known to cause eye disorders as a side effect of its therapeutic use. As the prophylactic effects of various eye drops have been reported, we retrospectively investigated the pr...

    Tetsuo Kume, Kana Akiyama, Takayuki Tsuchiya… in SN Comprehensive Clinical Medicine (2022)

  3. No Access

    Article

    Hand–foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients

    Hand–foot syndrome (HFS) is a typical skin disorder caused by the use of cytotoxic anticancer drugs and molecular targets. Similarly, various anticancer drugs have been used as a conditioning regimen for hemat...

    Tetsuo Kume, Rika Shimizu, Kana Akiyama, Takayuki Tsuchiya… in Supportive Care in Cancer (2022)

  4. Article

    Open Access

    Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients

    Busulfan is used as a conditioning regimen for hematopoietic stem cell transplantation and is known to cause seizures as a side effect. As various anticonvulsant drugs have been reported, we conducted a retros...

    Kana Akiyama, Tetsuo Kume, Masafumi Fukaya… in Cancer Chemotherapy and Pharmacology (2018)

    Download PDF (755 KB) View Article